- Home
- MBIO vs SNOA Comparison
MBIO vs SNOA Comparison
Compare MBIO & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBIO
- SNOA
- Stock Information
- Founded
- MBIO 2015
- SNOA 1999
- Country
- MBIO United States
- SNOA United States
- Employees
- MBIO N/A
- SNOA N/A
- Industry
- MBIO Biotechnology: Pharmaceutical Preparations
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- MBIO Health Care
- SNOA Health Care
- Exchange
- MBIO Nasdaq
- SNOA Nasdaq
- Market Cap
- MBIO 7.3M
- SNOA 6.4M
- IPO Year
- MBIO N/A
- SNOA 2007
- Fundamental
- Price
- MBIO $1.12
- SNOA $3.23
- Analyst Decision
- MBIO Strong Buy
- SNOA
- Analyst Count
- MBIO 1
- SNOA 0
- Target Price
- MBIO $100.00
- SNOA N/A
- AVG Volume (30 Days)
- MBIO 1.1M
- SNOA 3.5M
- Earning Date
- MBIO 05-27-2025
- SNOA 06-16-2025
- Dividend Yield
- MBIO N/A
- SNOA N/A
- EPS Growth
- MBIO N/A
- SNOA N/A
- EPS
- MBIO N/A
- SNOA N/A
- Revenue
- MBIO N/A
- SNOA $13,973,000.00
- Revenue This Year
- MBIO N/A
- SNOA $23.89
- Revenue Next Year
- MBIO N/A
- SNOA $25.45
- P/E Ratio
- MBIO N/A
- SNOA N/A
- Revenue Growth
- MBIO N/A
- SNOA 13.51
- 52 Week Low
- MBIO $1.01
- SNOA $1.75
- 52 Week High
- MBIO $65.00
- SNOA $9.40
- Technical
- Relative Strength Index (RSI)
- MBIO 36.90
- SNOA 53.06
- Support Level
- MBIO $1.01
- SNOA $3.02
- Resistance Level
- MBIO $1.22
- SNOA $3.37
- Average True Range (ATR)
- MBIO 0.07
- SNOA 0.22
- MACD
- MBIO 0.02
- SNOA -0.05
- Stochastic Oscillator
- MBIO 52.38
- SNOA 22.68
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.